Equities analysts predict that Juniper Pharmaceuticals Inc (NASDAQ:JNP) will announce ($0.16) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Juniper Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.20). Juniper Pharmaceuticals reported earnings of $0.88 per share in the same quarter last year, which indicates a negative year over year growth rate of 118.2%. The firm is expected to report its next earnings results on Tuesday, March 6th.

According to Zacks, analysts expect that Juniper Pharmaceuticals will report full-year earnings of ($0.49) per share for the current year. For the next year, analysts anticipate that the business will report earnings of $1.20 per share, with EPS estimates ranging from $0.19 to $2.21. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Juniper Pharmaceuticals.

How to Become a New Pot Stock Millionaire

A number of brokerages recently weighed in on JNP. ValuEngine downgraded shares of Juniper Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Roth Capital began coverage on shares of Juniper Pharmaceuticals in a research note on Tuesday, January 2nd. They set a “buy” rating and a $12.00 target price for the company. Finally, HC Wainwright reissued a “neutral” rating on shares of Juniper Pharmaceuticals in a research note on Monday, November 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $23.00.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. increased its stake in Juniper Pharmaceuticals by 3.4% in the second quarter. Goldman Sachs Group Inc. now owns 21,735 shares of the specialty pharmaceutical company’s stock valued at $110,000 after purchasing an additional 715 shares in the last quarter. Macquarie Group Ltd. bought a new stake in Juniper Pharmaceuticals in the third quarter valued at $129,000. Deutsche Bank AG increased its stake in Juniper Pharmaceuticals by 112.1% in the fourth quarter. Deutsche Bank AG now owns 37,181 shares of the specialty pharmaceutical company’s stock valued at $180,000 after purchasing an additional 19,653 shares in the last quarter. Bailard Inc. bought a new stake in Juniper Pharmaceuticals in the fourth quarter valued at $267,000. Finally, Nationwide Fund Advisors increased its stake in Juniper Pharmaceuticals by 5,500.0% in the second quarter. Nationwide Fund Advisors now owns 56,000 shares of the specialty pharmaceutical company’s stock valued at $283,000 after purchasing an additional 55,000 shares in the last quarter. 35.40% of the stock is owned by institutional investors and hedge funds.

Juniper Pharmaceuticals (JNP) traded up $0.15 during mid-day trading on Friday, hitting $8.70. 39,444 shares of the stock traded hands, compared to its average volume of 73,334. The company has a market capitalization of $92.72, a P/E ratio of 14.75 and a beta of 0.67. Juniper Pharmaceuticals has a 12-month low of $3.65 and a 12-month high of $8.95. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.00 and a quick ratio of 1.68.

COPYRIGHT VIOLATION NOTICE: “Juniper Pharmaceuticals Inc (JNP) Expected to Announce Earnings of -$0.16 Per Share” was published by Marea Informative and is the property of of Marea Informative. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.mareainformativa.com/2018/02/17/juniper-pharmaceuticals-inc-jnp-expected-to-announce-earnings-of-0-16-per-share.html.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.

Get a free copy of the Zacks research report on Juniper Pharmaceuticals (JNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.